Johnson & JohnsonJNJ
Daily Market Briefing
Latest briefing
Johnson & Johnson's Q3 2026 earnings miss expectations; stock drops 5.7%
Johnson & Johnson's Q3 2026 earnings report revealed a 5.7% decline in stock price, despite exceeding earnings expectations. The downturn was primarily due to underperformance in the medical devices division, influenced by geopolitical tensions in the Middle East.
Previous briefings
Johnson & Johnson's stock drops 5.7% amid Q3 earnings and MedTech sales miss
Johnson & Johnson's stock declined by 5.7% following its third-quarter earnings report, which revealed a 2.5% rise in medical technology sales that fell short of Wall Street expectations. The company also announced a potential spinoff of its DePuy Synthes orthopedics unit. Despite these challenges, J&J raised its full-year revenue and adjusted EPS guidance, driven by strong performance in its Innovative Medicine division.
Johnson & Johnson's Q3 profit plunges 96% due to talc litigation charges
Johnson & Johnson reported a 96% decline in net earnings for Q3 2026, primarily due to a one-time special charge related to talc litigation. Despite this, the company raised its full-year sales and adjusted earnings guidance, indicating strong operational performance.
Johnson & Johnson's RYBREVANT FASPRO™ shows 56% response rate in head and neck cancer trial
Johnson & Johnson's investigational treatment, RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), demonstrated a 56% overall response rate in a Phase 1b/2 study for first-line recurrent or metastatic head and neck squamous cell carcinoma. This promising result suggests potential for improved outcomes in this patient population.
Johnson & Johnson's ICOTYDE® shows sustained efficacy in plaque psoriasis treatment.
Johnson & Johnson announced positive two-year data from the Phase 3 ICONIC-TOTAL study, demonstrating that ICOTYDE® (icotrokinra) effectively treats difficult-to-manage plaque psoriasis. The study revealed that nearly 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved complete skin clearance at Week 112. These results affirm ICOTYDE®'s potential as a first-line systemic therapy for plaque psoriasis. ([jnj.com](https://www.jnj.com/media-center/press-releases?utm_source=openai))
Johnson & Johnson's stock drops 1.6% amid analyst target increases and pipeline updates
In the past 24 hours, Johnson & Johnson's (JNJ) stock declined by 1.6% to approximately $267.66. This movement occurred despite recent analyst target increases and positive developments in the company's drug pipeline. Notably, Bank of America raised its price target to $278 from $263, and JPMorgan increased its target to $285 from $270. Additionally, new data on the IMAAVY drug for generalized myasthenia gravis and positive results for Tremfya and Caplyta have been reported. However, concerns about potential third-quarter earnings falling below expectations and ongoing litigation costs may be contributing to the stock's recent performance.
Johnson & Johnson (JNJ) stock drops 1.21% amid $4 billion patent expiry concerns
Johnson & Johnson's (JNJ) stock declined by 1.21% to $252.93 on October 5, 2026, amid concerns over upcoming patent expirations in 2027, potentially impacting $4 billion in revenue. Despite this, the company reported positive Phase 3 ICOTYDE study results, showing 70% of patients achieved clear or almost clear skin at Week 112. Additionally, institutional investors have been adjusting their positions, with Park National Corp OH reducing its stake by 4.8% in the third quarter.
Johnson & Johnson reports durable psoriasis data; stock at $256.03.
Johnson & Johnson announced two-year data from the Phase 3 ICONIC-TOTAL study, showing that 70% of treated patients achieved clear or almost clear skin at Week 112, up from 57% at Week 16. The safety profile remained consistent over time. The stock closed at $256.03 on October 2, 2026, down 1.02% from the previous close.
Johnson & Johnson's stock drops 1.1% amid mixed pipeline news and analyst outlooks.
In the past 24 hours, Johnson & Johnson's stock experienced a 1.1% decline, closing at $255.94 on October 2, 2026. This movement was influenced by recent developments in the company's pipeline and analyst evaluations.
Johnson & Johnson's stock drops 1.69% to €226.93 amid new psoriasis treatment data
In the past 24 hours, Johnson & Johnson's stock declined by 1.69% to €226.93 following the release of two-year data from the Phase 3 ICONIC-TOTAL study on ICOTYDE (Icotrokinra) for plaque psoriasis. The study reported that 70% of treated patients achieved clear or almost clear skin at week 112, with complete healing rates of 60% on the scalp, 89% in the genital area, and 63% on hands and feet. Safety data remained consistent with known profiles, with no new safety signals identified.
Johnson & Johnson's stock drops 2.28% to $258.66 amid recent insider selling.
In the past 24 hours, Johnson & Johnson's stock declined by 2.28% to $258.66, influenced by recent insider selling activities. Over the past 90 days, insiders have sold approximately 97,569 shares valued at about $25.5 million. Additionally, the company continues to pay a quarterly dividend of $1.34 per share, yielding approximately 2.0%.
Johnson & Johnson's stock drops 1.6% amid analyst target hikes and pipeline updates
Despite recent analyst target increases and positive pipeline developments, Johnson & Johnson's stock declined by 1.6% to approximately $267.66. This movement reflects investor caution amid ongoing concerns over near-term earnings and valuation.
Johnson & Johnson's stock rises to $271.95 after positive Q2 2026 earnings report
Johnson & Johnson's stock price increased to $271.95 following the release of its Q2 2026 earnings report, which showed a 6.6% year-over-year sales growth to $25.3 billion and an adjusted earnings per share (EPS) of $2.90. The company also raised its 2026 sales and EPS guidance, reflecting strong operational performance.
Johnson & Johnson's stock rises 0.21% to $271.22 amid positive growth outlook.
Johnson & Johnson's stock experienced a modest increase following the company's optimistic growth projections. At the Deutsche Bank 2026 Healthcare Summit on September 17, 2026, CFO Joseph Wolk outlined a path to stronger sales, higher cash flow, and double-digit growth by the end of the decade. This positive outlook contributed to the stock's rise to $271.22, up 0.21% from the previous close.
Johnson & Johnson's stock rises 0.21% to $271.22 amid positive Caplyta trial results.
Johnson & Johnson's stock experienced a slight increase following favorable results from a Caplyta trial. The stock closed at $271.22 on September 25, 2026, up 0.21% from the previous close. The trial results are expected to positively impact the company's financial performance.
Johnson & Johnson's RYBREVANT FASPRO™ shows 56% response rate in head and neck cancer trial.
Johnson & Johnson's investigational treatment, RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), demonstrated a 56% overall response rate in a Phase 1b/2 study for first-line recurrent or metastatic head and neck squamous cell carcinoma. This promising result suggests potential for improved outcomes in this patient population.
Johnson & Johnson's stock remains steady at $270.22 following Q2 earnings beat.
In the past 24 hours, Johnson & Johnson's stock has maintained its position at $270.22, reflecting investor confidence after the company reported strong Q2 earnings. The stock's performance is also supported by positive analyst sentiment and recent strategic developments.
Johnson & Johnson's stock holds steady at $269.99 amid recent institutional activity.
In the past 24 hours, Johnson & Johnson's stock price has remained relatively stable at $269.99. Recent institutional investment activities, including increased holdings by OMERS Administration Corp and Ameritas Advisory Services LLC, suggest sustained confidence in the company's prospects. However, there have been minor reductions in holdings by other institutions, such as AMG National Trust Bank and Madison Asset Management LLC, indicating a cautious approach among some investors.
Johnson & Johnson's stock remains steady at $267.28 amid recent developments.
Over the past 24 hours, Johnson & Johnson's stock price has remained relatively unchanged, closing at $267.28 on September 16, 2026. This stability comes despite recent developments, including a Pennsylvania jury finding the company liable in a talc-related cancer case. The company has indicated plans to appeal the verdict.
Johnson & Johnson's RYBREVANT® plus chemotherapy shows longest survival in EGFR-mutated lung cancer
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) combined with chemotherapy has demonstrated the longest reported median overall survival in patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer (NSCLC). This dual-targeting approach, which addresses both EGFR and MET pathways, offers a significant advancement for a patient population with historically poor outcomes.
Lone Peak Global Investors reduces Johnson & Johnson stake by 9.8% in Q2 2026.
Lone Peak Global Investors LLC decreased its holdings in Johnson & Johnson by 9.8% during the second quarter of 2026, selling 7,153 shares and retaining 66,091 shares valued at $16.8 million. This reduction follows a series of similar moves by other institutional investors, including AMG National Trust Bank and Trinity Legacy Partners LLC, who also reduced their stakes in the same period. Despite these reductions, Johnson & Johnson reported strong quarterly earnings, with revenue of $25.31 billion and earnings per share of $2.90, exceeding analyst expectations. The company also declared a quarterly dividend of $1.34 per share, yielding approximately 2.0% annually.
Johnson & Johnson's stock price declines amid broader market pullback and profit-taking.
In the past 24 hours, Johnson & Johnson's stock has experienced a decline, influenced by a broader market pullback and profit-taking activities. Despite positive developments in the company's medical-device and pharmaceutical sectors, these market-wide factors have contributed to the downward movement.
Johnson & Johnson's stock declines 0.71% amid mixed institutional investment activities.
In the past 24 hours, Johnson & Johnson's (JNJ) stock experienced a slight decline of 0.71%, closing at $267.08. This movement coincided with recent institutional investment activities, including a 1.9% increase in holdings by Braun Stacey Associates Inc., which now owns 156,008 shares valued at approximately $39.6 million. Conversely, Addison Advisors LLC reduced its stake by 78.4%, selling 7,675 shares and retaining 2,109 shares valued at about $536,000. These mixed investment actions may reflect varied institutional perspectives on JNJ's current valuation and prospects.
Johnson & Johnson's stock dips amid insider selling and market volatility
In the past 24 hours, Johnson & Johnson's stock has experienced a decline, influenced by recent insider selling activities and broader market fluctuations. Notably, an executive vice president sold 11,070 shares at $274.74 on September 2, 2026. Additionally, market analysts have observed a more significant dip in JNJ's stock compared to the broader market.
Johnson & Johnson's stock drops 1.1% to $275.23 amid mixed investor activity
In the past 24 hours, Johnson & Johnson's (JNJ) stock experienced a 1.1% decline, closing at $275.23. This movement coincided with varied institutional investment activities, including a 16.4% increase in holdings by Bank of Nova Scotia and a 36.9% reduction by Barrow Hanley Mewhinney & Strauss LLC. These mixed actions reflect differing investor sentiments and strategies.
Johnson & Johnson's stock price remains steady at $275.21 amid recent developments.
Over the past 24 hours, Johnson & Johnson's stock price has remained steady at $275.21. Recent developments include the company's participation in the Deutsche Bank 2026 Healthcare Summit on September 17, 2026, and UBS initiating coverage with a 'Buy' rating and a price target of $320, up from $280. Additionally, the company announced a quarterly dividend of $1.34 per share, payable on September 8, 2026.
Johnson & Johnson's stock rises 1.1% to $273.11 amid positive pipeline developments
In the past 24 hours, Johnson & Johnson's stock increased by 1.1%, closing at $273.11. This uptick is attributed to recent positive developments in the company's pharmaceutical pipeline, including the European Commission's approval of a TECVAYLI combination for multiple myeloma and the FDA's approval of Imaavy for warm autoimmune hemolytic anemia. These advancements are expected to bolster future pharmaceutical sales and offset revenue declines from older drugs.
Johnson & Johnson's stock remains near record highs following strong Q2 2026 earnings.
Johnson & Johnson's stock is trading close to its 52-week high, supported by robust Q2 2026 earnings and an optimistic full-year outlook. The company reported a 6.6% increase in revenue to $25.3 billion and raised its 2026 sales guidance to $101.1 billion, with adjusted earnings per share projected at $11.68. Additionally, the stock's valuation remains attractive, trading at approximately 22.3 times projected earnings for 2026.
Johnson & Johnson's stock extends 54% rally as Q2 2026 drug shift lifts outlook
Johnson & Johnson's stock has surged over 50% in the past year, driven by a strategic shift towards newer immunology drugs and an increased full-year sales forecast. The company's Q2 2026 results highlighted a significant rise in TREMFYA sales, offsetting declines in older drugs like STELARA. This positive momentum has bolstered investor confidence, with the stock trading near record highs.
Johnson & Johnson's stock reaches near 52-week high after Q2 earnings beat
Johnson & Johnson's stock has surged to near its 52-week high following a strong second-quarter earnings report. The company reported a 6.6% year-over-year increase in revenue, reaching $25.31 billion, and an adjusted earnings per share (EPS) of $2.90, surpassing analyst expectations. Additionally, the FDA approved IMAAVY, the first treatment for warm autoimmune hemolytic anemia, expanding J&J's presence in rare diseases.
Analyze any chart in seconds
This is today's read on Johnson & Johnson. Point your camera at any chart and ChartDetector AI gives you a full technical analysis in seconds — free on iPhone and Android.
AI-generated from public news sources. Not financial advice.
